Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Excessive Daytime Sleepiness: later-stage trial registry
2 of 4 indexed Excessive Daytime Sleepiness trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Excessive Daytime Sleepiness: 4 US clinical trials tracked, 2 recruiting.
Excessive Daytime Sleepiness is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Cephalon, running 1 of these trials.
Enrollment posture brief
Registry condition excessive-daytime-sleepiness
OPEN 2 | RECR 50% | LATE 2 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Excessive Daytime Sleepiness lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Excessive Daytime Sleepiness on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Excessive Daytime Sleepiness is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Centessa Pharmaceuticals (UK) Limited
NCT07082829
Impact of Bright Light Therapy on Prader-Willi Syndrome
Maimonides Medical Center
NCT05939453
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
Cephalon
NCT00228566
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Axsome Therapeutics
NCT04789174
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Excessive Daytime Sleepiness records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Excessive Daytime Sleepiness trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Excessive Daytime Sleepiness page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Excessive Daytime Sleepiness trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cephalon sponsors the most Excessive Daytime Sleepiness trials on record, review their full trial history before evaluating a specific study. See Cephalon's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Excessive Daytime Sleepiness condition card totals 4 registered trials; most-linked intervention Armodafinil; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.